Lipid Drug Conjugate (LDC) Nanoparticles as Autolymphotrophs for Oral Delivery of Methotrexate
The objective of the study was to develop lipid drug conjugate nanoparticles (LDC-NPs) of anticancer drug methotrexate (MTX) for oral delivery that faces problems of low and variable bioavailability. The MTX loaded LDC-NPs significantly enhanced bioavailability and reduced MTX associated
gastrointestinal toxicity even in higher doses recommended for anticancer therapy.
Keywords: LIPID-DRUG CONJUGATES; LYMPHATIC DELIVERY; METHOTREXATE; NANOPARTICLES
Document Type: Research Article
Publication date: 01 January 2011
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content